B-Cell Acute Lymphoblastic Leukemia research hub
4 indexed studies · 1 currently recruiting
- active not recruitingPHASE2
Study of Efficacy and Safety of Tisagenlecleucel in HR B-ALL EOC MRD Positive Patients
This study looks at a new treatment called tisagenlecleucel for children and young adults (ages 1-25) with a type of blood cancer called B-cell acute lymphoblastic leukemia (B-ALL). It aims to see how well it works and if it's safe after standard first-line treatment.
United States · Belgium · Canada - authorisedPhase I and Phase II (Integrated)- First administration to humans
BOB1-TCR therapy for treatment of relapsed or refractory B-cell malignancies - A Phase 1/2 clinical trial
This study is looking at a new type of treatment for certain blood cancers like leukaemia and lymphoma. It's called BOB1-TCR therapy. The first part checks if the treatment is safe and what dose to use, and the second part looks at how well it works.
Netherlands - authorisedTherapeutic confirmatory (Phase III)
The INFLUENCE Trial: Improving EveNt Free Survival by Optimizing FLUdarabine Exposure during LymphodepletioN for CAR T CEll Therapy: a randomized, multi-center study of children and young adults with B-cell acute lymphoblastic leukemia
This study looks at how a medicine called fludarabine, used with CAR T-cell therapy, affects children and young adults with a type of blood cancer called B-cell Acute Lymphoblastic Leukemia. It compares different ways of giving fludarabine to see which works best.
Spain · Germany · Netherlands - recruitingPHASE1, PHASE2
Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)
This study is testing a new drug, Zilovertamab Vedotin, for children and young adults aged 6 months to 25 years with certain blood cancers (like some types of leukaemia and lymphoma) and solid tumours (like neuroblastoma and Ewing sarcoma) that have come back or not responded to previous treatments.
United States · Australia · Belgium